ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

BerGenBio (No_rec, TP: NOK) - Decision to end BGBC016 trial – recommen...

BerGenBio announced yesterday that it has decided to discontinue its 1L STK11m NSCLC trial due to the weak preliminary results. We already believed the value of the data would be limited, but this is a significant setback for the company. BerGenBio said that it is entering a new phase, in which strategic alternatives will be explored. As a result of the trial discontinuation, the company’s financial situation, and limited available information on the potential alternatives being explored, we hav...

BerGenBio (Sell, TP: NOK5.00) - Decision to end BGBC016 trial

BerGenBio announced tonight that it has decided to discontinue its 1L STK11m NSCLC trial due to preliminary results not being strong enough. We already believed the value of the data would be limited, and this is a significant setback for the company. The company said that it is now entering a new phase in which strategic alternatives will be explored.

Merck & Co Inc: 3 directors

Three Directors at Merck & Co Inc bought/sold after exercising options 20,194 shares at between 88.250USD and 88.755USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...

BerGenBio (Sell, TP: NOK5.00) - Q2 report

BerGenBio said that its BGBC016 trial is progressing as planned, with all sites in the phase IIa part activated. It expects a phase IIa interim analysis at end-2024. We reiterate our SELL and NOK5 target price.

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

BerGenBio (Sell, TP: NOK0.05) - Q1 report

While the Q1 report contained no large surprises, the company announced earlier this week a clinical collaboration with UT Health San Antonio and Sobi to evaluate bemcentinib in combination with Sobi’s pacritinib in patients with advanced lung adenocarcinoma. We reiterate our SELL and NOK0.05 target price on our concerns about the company’s ability to generate sufficient investor interest during its financial runway and ahead of the next need for financing.

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

BerGenBio (Sell, TP: NOK0.05) - Our concerns remain

While opex fell sharply in 2023 and YOY in Q4, and management maintained the timeline for its BGBC016 study, we remain concerned about a lack of major share-price catalysts ahead of the next needed capital raise. We reiterate our SELL and NOK0.05 target price.

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Northern Lights

BerGenBio (Sell, TP: NOK0.05) - Too little before it’s too late

Following the recent rights issue and detrimental terms for the stock, we remain concerned about the company’s ability to produce substantial share-price catalysts during its financial runway (we estimate until 2024e). We struggle to see the current phase Ib/IIa study producing results considered attractive enough for investors ahead of the next needed capital raise. We reiterate our SELL and have cut our target price to NOK0.05 (0.11).

Moody's assigns A1 rating to Merck's sr. notes; stable outlook

Moody's Investors Service ("Moody's") assigned an A1 rating to the new senior unsecured notes offering of Merck & Co., Inc. ("Merck"). There are no changes to Merck's existing ratings including the A1 senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains stable. ...

Northern Lights

BerGenBio (Sell, TP: NOK1.00) - Detrimental rights issue

The company announced that it intends to carry out a rights issue of shares to raise gross proceeds of up to NOK250m, with preferential subscription rights for existing shareholders. We see the terms of the financing as detrimental to the stock and we also struggle to identify substantial share-price catalysts for the next 12–18 months. Thus, we have cut our target price to NOK1 (9) and downgraded to SELL (HOLD).

Moody's: Merck's acquisition of Prometheus will strengthen immunology ...

Moody's Investors Service commented that Merck & Co., Inc.'s acquisition of Prometheus Biosciences, Inc. ("Prometheus") for approximately $10.8 billion will enhance Merck's pipeline in immunology. However, the acquisition also entails pipeline and commercial execution risk, given the high price tag....

Merck & Co., Inc.: Merck's acquisition of Prometheus will strengthen i...

The deal has pipeline and commercial execution risk, but Merck's M&A capacity is high

Merck & Co., Inc. - December 2022 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.